On the Usefulness of Two Small-Scale In Vitro Setups in the Evaluation of Luminal Precipitation of Lipophilic Weak Bases in Early Formulation Development.

PBPK modelling biorelevant biphasic dissolution dissolution-permeation. in vitro techniques precipitation supersaturation

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
16 Mar 2020
Historique:
received: 18 02 2020
revised: 08 03 2020
accepted: 11 03 2020
entrez: 20 3 2020
pubmed: 20 3 2020
medline: 20 3 2020
Statut: epublish

Résumé

A small-scale biphasic dissolution setup and a small-scale dissolution-permeation (D-P) setup were evaluated for their usefulness in simulating the luminal precipitation of three lipophilic weak bases-dipyridamole, ketoconazole and itraconazole. The transition from the gastric to intestinal environment was incorporated into both experimental procedures. Emulsification during the biphasic dissolution experiments had a minimal impact on the data, when appropriate risk mitigation steps were incorporated. Precipitation parameters estimated from the in vitro data were inputted into the Simcyp® physiologically based pharmacokinetic (PBPK) modelling software and simulated human plasma profiles were compared with previously published pharmacokinetic data. Average C

Identifiants

pubmed: 32188116
pii: pharmaceutics12030272
doi: 10.3390/pharmaceutics12030272
pmc: PMC7151110
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Horizon 2020
ID : 674909

Déclaration de conflit d'intérêts

Karl J. Box is an employee of Pion Inc. (UK) Ltd. The funders/company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results

Références

J Pharm Sci. 2010 Nov;99(11):4525-34
pubmed: 20845451
J Pharm Sci. 2016 Sep;105(9):2677-2684
pubmed: 26505884
Eur J Drug Metab Pharmacokinet. 1991 Jul-Sep;16(3):197-201
pubmed: 1814737
J Pharm Sci. 2002 Jun;91(6):1414-22
pubmed: 12115841
J Pharm Sci. 1996 Oct;85(10):1060-3
pubmed: 8897271
Int J Clin Pharmacol Res. 1990;10(5):271-6
pubmed: 2079384
Mol Pharm. 2017 Dec 4;14(12):4305-4320
pubmed: 28771009
Antimicrob Agents Chemother. 1986 Aug;30(2):206-10
pubmed: 3767339
AAPS PharmSciTech. 2019 Feb 13;20(3):113
pubmed: 30761437
Eur J Pharm Biopharm. 2018 Nov;132:231-236
pubmed: 29959034
J Pharm Pharmacol. 2012 Nov;64(11):1549-59
pubmed: 23058042
J Pharm Sci. 2010 Jul;99(7):3246-65
pubmed: 20166204
Pharm Res. 2011 Dec;28(12):3145-58
pubmed: 21674262
Mol Pharm. 2017 Nov 6;14(11):3801-3814
pubmed: 28898584
J Pharm Sci. 2018 Jan;107(1):307-316
pubmed: 28919384
AAPS PharmSciTech. 2018 Oct;19(7):2851-2858
pubmed: 29872977
AAPS J. 2016 Nov;18(6):1512-1523
pubmed: 27600136
Mol Pharm. 2017 Dec 4;14(12):4321-4333
pubmed: 28817288
Pharm Res. 2018 Jun 20;35(8):161
pubmed: 29926245
Biopharm Drug Dispos. 2012 Oct;33(7):378-402
pubmed: 22847296
Eur J Pharm Sci. 2014 Sep 30;61:32-9
pubmed: 24413061
Eur J Pharm Sci. 2019 Sep 1;137:105001
pubmed: 31301486
J Pharm Sci. 2019 Apr;108(4):1604-1618
pubmed: 30476508
Mol Pharm. 2010 Oct 4;7(5):1458-65
pubmed: 20704265
Mol Pharm. 2017 Jul 3;14(7):2437-2449
pubmed: 28591516
Eur J Pharm Sci. 2017 Mar 30;100:42-55
pubmed: 28011125
J Pharm Sci. 2016 Sep;105(9):2712-2722
pubmed: 26921120
Mycoses. 1989;32 Suppl 1:67-87
pubmed: 2561187
Int J Pharm. 2017 Jun 15;525(1):211-217
pubmed: 28414135
J Pharm Sci. 2018 Jan;107(1):476-487
pubmed: 28666964
AAPS J. 2009 Jun;11(2):225-37
pubmed: 19381840
J Pharm Sci. 2016 Sep;105(9):2804-2814
pubmed: 27020985
Mol Pharm. 2016 Jun 6;13(6):1763-78
pubmed: 26926043
AAPS J. 2018 Mar 29;20(3):57
pubmed: 29600330
J Pharm Pharmacol. 2019 Apr;71(4):536-556
pubmed: 29956338
Acta Pharmacol Toxicol (Copenh). 1979 May;44(5):391-9
pubmed: 474151
Int J Pharm. 2004 Apr 15;274(1-2):245-60
pubmed: 15072800
AAPS J. 2018 May 24;20(4):71
pubmed: 29797293
Eur J Pharm Biopharm. 2015 Jun;93:173-82
pubmed: 25836053
Eur J Pharm Biopharm. 2016 Aug;105:166-75
pubmed: 27297570
J Pharm Pharmacol. 2018 Oct;70(10):1315-1323
pubmed: 30062721
Antimicrob Agents Chemother. 1984 Jan;25(1):1-3
pubmed: 6322675
Clin Pharmacokinet. 1998 Dec;35(6):461-73
pubmed: 9884817
AAPS PharmSciTech. 2018 Oct;19(7):2859-2865
pubmed: 29876792

Auteurs

Patrick J O'Dwyer (PJ)

Pion Inc. (UK) Ltd., Forest Row, East Sussex RH18 5DW, UK.
Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, GR 157 84 Zografou, Greece.

Georgios Imanidis (G)

University of Applied Sciences Northwest. Switzerland. School of Life Sciences, Institute of Pharma Technology, Hofackerstrasse 30, 4132 Muttenz, Switzerland.
University of Basel, Department of Pharmaceutical Sciences, CH 4056 Basel, Switzerland.

Karl J Box (KJ)

Pion Inc. (UK) Ltd., Forest Row, East Sussex RH18 5DW, UK.

Christos Reppas (C)

Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, GR 157 84 Zografou, Greece.

Classifications MeSH